Last reviewed · How we verify
NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
trial testing Pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell. Approved for marketing.
Quick facts
| Lead sponsor | Loxo Oncology, Inc. |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Pirtobrutinib — full drug profile →
Conditions studied
- Leukemia, Lymphocytic, Chronic, B-Cell — all drugs for Leukemia, Lymphocytic, Chronic, B-Cell →
- Lymphoma, Lymphocytic, Small — all drugs for Lymphoma, Lymphocytic, Small →
- Lymphoma, Mantle-Cell — all drugs for Lymphoma, Mantle-Cell →
- Waldenstrom Macroglobulinemia — all drugs for Waldenstrom Macroglobulinemia →
Sponsor
Loxo Oncology, Inc. — full company profile →
Who can join
18 and older, any sex, with Leukemia, Lymphocytic, Chronic, B-Cell or Lymphoma, Lymphocytic, Small. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A, Montoya S, Safronenka A, Taylor J. · · 2023 · cited 23× · PMID 38137005 · DOI 10.3390/genes14122182 -
Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
Muñoz J, Sarosiek S, Castillo JJ. · · 2023 · cited 8× · PMID 36723874 · DOI 10.1093/oncolo/oyac260 -
Treatment of Richter's Transformation with Novel Therapies.
Bajwa A, Habib A, Kittai AS. · · 2024 · cited 6× · PMID 38194201 · DOI 10.1007/s11899-023-00721-8 -
Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?
Solia E, Kastritis E. · · 2024 · PMID 39734591 · DOI 10.1177/20406207241308771
Verify or expand the search:
- PubMed search for NCT05172700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pirtobrutinib
Trials testing the same drug.
- NCT07525817 — A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma · not yet recruiting
- NCT07428707 — Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib · EARLY_PHASE1 · recruiting
- NCT07207785 — PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · Phase 2 · not yet recruiting
- NCT07342478 — ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL · Phase 3 · not yet recruiting
- NCT07255963 — Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL · Phase 2 · recruiting
Other recruiting trials for Leukemia, Lymphocytic, Chronic, B-Cell
Currently open trials in the same condition.
- NCT06364423 — Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias · Phase 1, PHASE2 · recruiting
- NCT05963074 — A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemi · Phase 2 · recruiting
- NCT06299540 — Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lym · recruiting
- NCT05947851 — A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) · Phase 3 · recruiting
- NCT05424822 — A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin · Phase 1 · active not recruiting
Other Loxo Oncology, Inc. trials
Trials by the same sponsor.
- NCT06104683 — A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis · Phase 2 · withdrawn
- NCT05324124 — A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed
- NCT05176314 — A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants · Phase 1 · completed
- NCT05136404 — A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed
- NCT05089019 — A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05172700 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loxo Oncology, Inc.
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing